Editor's Note: At ESMO 2026, Professor Liangyou Gu from the Chinese PLA General Hospital reported a prospective study evaluating the diagnostic and staging performance of [68Ga]Ga-DPI-4452 PET/CT targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC). Historically, ccRCC staging has relied heavily on CT/MRI, while the use of FDG PET/CT has been limited by its lack of specificity. How to achieve more precise characterization and staging has therefore remained a major clinical challenge. Against this backdrop, Oncology Frontier – UroStream invited Professor Liangyou Gu to provide an in-depth interpretation of the rationale for selecting this imaging target and the potential future applications of this novel imaging technique.

Oncology Frontier – UroStream: In this prospective study, why did you select CAIX as an imaging target for ccRCC? What diagnostic challenges that are difficult to resolve with conventional imaging do you most hope this novel PET/CT technique will address?

Professor Liangyou Gu: First, selecting the right target is the most critical prerequisite for PET/CT imaging. We have traditionally used FDG PET/CT, but it reflects glucose uptake and lacks tumor specificity. Our decision to select CAIX as the target was mainly based on three considerations:

First, CAIX is highly expressed in clear cell renal cell carcinoma, with high expression observed in more than 95% of patients, while its expression in normal tissues is very low. This creates an ideal therapeutic and imaging window for targeting.

Second, CAIX is itself a commonly used marker for the pathological diagnosis of ccRCC.

Third, this target was not first proposed by our team; rather, its selection builds on a substantial body of previous validation research. After considering all these factors, we ultimately selected CAIX as the diagnostic imaging target for ccRCC.

Turning to clinical needs, we hope this technique will address two types of diagnostic challenges that conventional imaging struggles to resolve. The first is diagnostic characterization. In some patients, conventional CT or MRI cannot determine whether a lesion is benign or malignant, including in certain specific situations such as cystic renal cancers. Conventional imaging may be inconclusive, whereas highly specific CAIX PET/CT can provide a more definitive answer to the questions: “Is the lesion malignant?” and “Is it ccRCC?”

The second is precision staging. Precise diagnosis is a prerequisite for precision treatment. Conventional CT/MRI primarily addresses the primary tumor, but its assessment of metastatic lesions is limited in terms of both anatomical coverage and diagnostic performance. Although FDG PET/CT enables whole-body imaging, it also has limitations in detecting renal cancer metastases and can sometimes even lead to misdiagnosis. As demonstrated by the findings of our study, CAIX PET/CT detected significantly more lesions than FDG PET/CT. It offers clear advantages in answering questions that directly determine treatment decisions: whether metastases are present, where they are located, and how many metastatic lesions there are.

Oncology Frontier – UroStream: Could you elaborate on the most noteworthy diagnostic and staging findings of this study? For both imaging-positive and imaging-negative lesions, how did the study establish more reliable pathological or follow-up reference standards to avoid insufficient verification that could affect the assessment of diagnostic accuracy and the value of detecting additional lesions?

Professor Liangyou Gu: This is a very important question. It touches on a central issue that we must always consider when evaluating diagnostic performance: the “gold standard.” If a test identifies a lesion as positive, is it truly positive?

Regarding the study design, all primary lesions in Cohort A had pathological results to support their diagnostic characterization. For metastatic lesions, however, a patient often has lesions at multiple sites, making it impractical to perform needle biopsies on every lesion. We therefore adopted a reference approach combining pathology and clinical assessment: pathological findings served as the reference standard for primary lesions, while metastatic lesions were assessed clinically based on clinical observation, contemporaneous imaging, and the results of other examinations. By combining pathological findings with clinical and imaging assessments, we were able to establish a more detailed and reliable reference standard for evaluating diagnostic accuracy. This reference framework is also consistent with the approaches adopted in previous studies of a similar nature.

Oncology Frontier – UroStream: Looking ahead, at which stages of clinical decision-making do you believe this imaging approach is most likely to demonstrate value? Moving from “detecting more lesions” to “improving patient management,” what further multicenter validation will be needed to clarify the appropriate patient populations and optimal timing of examinations?

Professor Liangyou Gu: The development of radionuclide-based approaches, from diagnosis to potential future treatment, is a long journey. The pathway currently being pursued in renal cancer largely follows the established development pathway of PSMA PET/CT in prostate cancer.

First, imaging findings can directly change treatment decisions. Precision staging is the foundation of precision treatment. We have already encountered clinical cases in which the metastatic status indicated by CAIX PET/CT completely overturned the original assessment, changing the classification from “no metastases” to “metastatic disease” and consequently altering the treatment decision. In other cases, patients initially considered to have a solitary metastatic lesion were found to have multiple metastases, leading to similarly substantial changes in treatment strategy. We hope that, following multicenter validation, this approach can become a standard diagnostic tool for renal cancer. More accurate staging will inevitably lead to more appropriate treatment decisions, particularly for patients with locally advanced or metastatic disease.

Second, it may serve as a complementary tool for treatment response assessment. Our study included an exploratory case involving a patient whose tumor showed very high CAIX expression and pronounced tracer uptake before treatment. After treatment, uptake decreased substantially and became almost undetectable; postoperative tissue analysis also revealed virtually no detectable CAIX expression. In the future, this tool may help predict and assess treatment response. For example, some patients may show little reduction in tumor size according to RECIST criteria, yet the tumor may already have almost no residual solid component. CAIX PET/CT may be able to identify precisely these patients, making it an important complement to conventional treatment response assessment.

A more long-term direction is theranostics. Radionuclide therapy for prostate cancer is already widely used in clinical practice, whereas its application in renal cancer remains under investigation. If CAIX-based radioligand therapy becomes a treatment option for renal cancer in the future, we could first use CAIX PET/CT to screen and identify suitable patients, and then guide subsequent radioligand therapy. I believe this integration of diagnosis and treatment is a promising direction to look forward to.